Mycobacterium tuberculosis in patient samples. [IMM / UZH]
A research team from the Institute of Medical Microbiology at the University of Zurich and the National Center for Mycobacteria has carried out a large-scale study with more than 6800 patient samples to examine molecular-based methods for the detection of mycobacterial pathogens. Because many mycobacteria only grow at a slow pace, routine detection using bacteria cultures in highly specialized and expensive high-safety labs takes several weeks to complete. The subsequent susceptibility test to determine the appropriate medicine also takes 1 to 2 weeks.
“For patients and doctors, this long waiting period is an unnecessary test of their patience”, says Peter Keller, M.D., from the Institute of Medical Microbiology at the UZH. “By comparison, with molecular detection methods, most patients know after 1 or 2 days whether they have an infection with tuberculosis pathogens or with nontuberculous mycobacteria.”
Mycobacteria cause various illnesses. Mycobacterium tuberculosis, the main representative of this genus, is the causative agent of tuberculosis, which killed around 1.5 million people worldwide in 2014. Nontuberculous mycobacteria can trigger pulmonary infections, lymph node infections, and skin diseases in patients with compromised immune systems. On account of more and more people with chronic lung diseases and the success of transplants, these difficult-to-treat infections have been on the rise continuously in recent decades.
For their study (“Diagnostic Molecular Mycobacteriology in Regions With Low Tuberculosis Endemicity: Combining Real-Time PCR Assays for Detection of Multiple Mycobacterial Pathogens with Line Probe Assays for Identification of Resistance Mutations”), published in EBioMedicine, the researchers developed a diagnostic algorithm to detect mycobacteria directly from the patient sample using genetic analysis. With this molecular detection method, the patient samples were examined continuously over 3 years and compared with the results from the bacteria cultures for more than 3000 patients. The new molecular-based methods were found to be just as accurate as the lengthy culture-based techniques used to date.
In addition, the molecular analysis makes it possible for the first time also to detect the nontuberculous mycobacteria directly from the patient sample within just a few hours, according to Dr. Keller. This means that suitable therapeutic measures can be initiated much more quickly. By contrast, if the patient has a tuberculosis infection, a further molecular assay is carried out to test susceptibility to the main tuberculosis drugs rifampicin and isoniazid. “This also showed that the molecular-based method reliably predicts the culture-based resistance results. It is possible to obtain certainty much sooner of whether the therapy with standard medicines chosen is likely to be successful”, explains Dr. Keller.